Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma
The assessment of updated clinical trial data, optimal dosing strategies, and integration of bispecific antibodies into current relapsed/refractory multiple myeloma treatment paradigms were the focus of conversation during a Frontline Forum event. …